

Press release 2015-11-10

## **WntResearch presents a commentary to the Foxy-5 phase 1 report**

WntResearch today announces that a commentary report on the Foxy-5 phase 1 clinical data will be released on the company homepage ([www.wntresearch.com](http://www.wntresearch.com)) in the evening of November 10, under the heading 'Investor & media', subheading 'Events & presentations'.

CEO, Nils Brünner explains: *"The recent publication of the interim report from the Foxy-5 clinical Phase 1 study has raised a lot of questions. This has prompted us to write a clarification on how WntResearch values the results"*.

### **For additional information please contact:**

Nils Brünner, CEO

E-mail: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)

Telephone: + 45 2614 4708

### **About WntResearch**

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.